MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.
Secondary Hyperparathyroidism (SHPT) in Subjects with Chronic Kidney Disease (CKD) on Hemodialysis
DRUG: MT1013|DRUG: MT1013|DRUG: Etelcalcetide Hydrochloride|DRUG: Placebo
Percentage of participants with > 30% reduction from baseline in mean iPTH during the efficacy assessment phase, Weeks 22 to 27, inclusive
Percentage of participants with > 50% reduction from baseline in mean iPTH during the efficacy assessment phase, Weeks 22 to 27, inclusive
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.